Received FDA clearance to initiate Phase 3 registrational study for ersodetug for the treatment of hypoglycemia due to tumor hyperinsulinism². Johnson & Johnson Presented neoadjuvant TAR-200 plus ...
Surgical intervention for severe post-RYGB hypoglycemia includes pancreatic resection, RYGB reversal, and gastric pouch restriction, with resolution of symptoms in 67%, 76%, and 82% of patients, ...